In: In vivo CAR-T
What this is
- How it works
- Reprograms the patient's own immune T cells, inside the body, to hunt one kind of cell, such as cancerous B cells. Standard CAR-T does this in a lab.In vivo BCMA CAR-T
- Tested for
- Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type, Neoplasm, Hemostatic Disorders, Vascular Disorder, Paraproteinemias and 6 more
- Main trialPhase 1
- “The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.”In the company’s words, NCT07075185 on ClinicalTrials.gov
Coming up1
- Mar 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Mar 2027 | A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026